Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Reactogenicity of Infanrix-IPV/Hib in Infants
NCT00964028Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2009
- Primary completion
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine in diphtheria, Tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (Hib), sponsored by GSK. Started Dec 2009; status: completed.
02
Drugs
diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00964028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964028.